The pioneering AbiProt® technology is a completely new concept in antibody discovery. It has proven capabilities to deliver antibodies against clinically meaningful targets, previously undruggable with conventional antibody technologies. AbiProt® is a scalable breakthrough innovation with potential to impact the lives of millions of patients. Some call it a revolution, we call it magic.
About AbiProt®
We focus on developing new antibody medicines in pain. These conditions are in strong need of effective therapies that can only be solved by breakthrough science and innovation. The AbiProt® technology has proven to deliver precision antibodies against clinically meaningful targets.
We are a team of pharma professionals and young talent with strong scientific and business acumen. We have a proven track record of bringing drugs to the market, excellence in science, and product development. We are devoted to change the life of patients through innovation.
About our Team
Recent news
More news22 August 2024 News
Stockholm, Sweden - August 22, 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt® technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties.
18 June 2024 News
Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers
15 January 2024 News
Oblique Therapeutics presents at Redeye
